Aratana Therapeutics (PETX) PT Set at $10.00 by HC Wainwright

HC Wainwright set a $10.00 target price on Aratana Therapeutics (NASDAQ:PETX) in a report issued on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently weighed in on PETX. Zacks Investment Research raised Aratana Therapeutics from a hold rating to a buy rating and set a $5.75 price target for the company in a report on Thursday, August 16th. ValuEngine raised Aratana Therapeutics from a sell rating to a hold rating in a report on Wednesday, August 15th. Finally, BidaskClub cut Aratana Therapeutics from a buy rating to a hold rating in a report on Wednesday, October 17th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Aratana Therapeutics presently has an average rating of Buy and a consensus price target of $8.17.

PETX stock opened at $6.82 on Monday. Aratana Therapeutics has a fifty-two week low of $3.67 and a fifty-two week high of $7.28. The firm has a market cap of $325.30 million, a P/E ratio of -7.03 and a beta of 1.95. The company has a quick ratio of 2.44, a current ratio of 3.17 and a debt-to-equity ratio of 0.02.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. The firm had revenue of $21.56 million during the quarter, compared to analysts’ expectations of $5.70 million. As a group, equities research analysts expect that Aratana Therapeutics will post -0.25 EPS for the current fiscal year.

In other news, insider Ernst Heinen sold 10,372 shares of Aratana Therapeutics stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $5.15, for a total value of $53,415.80. Following the completion of the sale, the insider now directly owns 157,406 shares of the company’s stock, valued at approximately $810,640.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Steven St sold 11,513 shares of Aratana Therapeutics stock in a transaction on Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total value of $67,466.18. Following the completion of the sale, the insider now directly owns 562,720 shares of the company’s stock, valued at $3,297,539.20. The disclosure for this sale can be found here. Insiders sold a total of 97,577 shares of company stock valued at $580,191 over the last three months. Insiders own 5.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. American Century Companies Inc. acquired a new stake in shares of Aratana Therapeutics in the 2nd quarter valued at $195,000. Bank of Montreal Can increased its stake in shares of Aratana Therapeutics by 152.9% in the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 31,053 shares during the period. Jane Street Group LLC increased its stake in shares of Aratana Therapeutics by 683.0% in the 1st quarter. Jane Street Group LLC now owns 81,952 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 71,486 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Aratana Therapeutics by 23.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after buying an additional 17,300 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of Aratana Therapeutics in the 2nd quarter valued at $487,000. 66.22% of the stock is owned by institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: Do stock splits help investors?

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply